A
Amulya Nanisetti
Publications - 6
Citations - 519
Amulya Nanisetti is an academic researcher. The author has contributed to research in topics: CD8 & SLAMF7. The author has an hindex of 4, co-authored 6 publications receiving 461 citations.
Papers
More filters
Journal ArticleDOI
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Eric D. Hsi,Roxanne Steinle,Balaji Balasa,Susann Szmania,Aparna Draksharapu,Benny P. Shum,Mahrukh Huseni,David M. W. Powers,Amulya Nanisetti,Yin Zhang,Audie Rice,Anne van Abbema,Melanie Wong,Gao Liu,Fenghuang Zhan,Myles B.C. Dillon,Shihao Chen,Susan Rhodes,Franklin Fuh,Naoya Tsurushita,Shankar Kumar,Vladimir Vexler,John D. Shaughnessy,Bart Barlogie,Frits van Rhee,Mohamad A. Hussein,Daniel E. H. Afar,Marna Williams +27 more
TL;DR: It is suggested that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with Hu Luc63 for the treatment of multipleMyeloma.
Journal ArticleDOI
Isolation and whole genome sequencing of fetal cells from maternal blood towards the ultimate non-invasive prenatal testing
Fang Chen,Ping Liu,Ying Gu,Zhu Zhu,Amulya Nanisetti,Zhangzhang Lan,Zhiwei Huang,Jia Sophie Liu,Kang Xiongbin,Yuqing Deng,Liqiong Luo,Dan Jiang,Qiu Yong,Pan Jianchang,Jun Xia,Ken Xiong,Chao Liu,Xie Lin,Qianyu Shi,Jing Li,Xiuqing Zhang,Wei Wang,Snezana Drmanac,Lars Bolund,Lars Bolund,Hui Jiang,Radoje Drmanac,Xun Xu +27 more
TL;DR: The purpose of this study was to develop a methodology of isolating fetal cells from maternal blood and use deep sequence demonstrating the promise for complete and accurate genetic screening compared to other non‐invasive prenatal testing.
Journal ArticleDOI
CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.
Eric D. Hsi,Roxanne Steinle,Balaji Balasa,Aparna Draksharapu,Benny Shum,Marukh Huseni,David M. W. Powers,Amulya Nanisetti,Marna Williams,Vladimir Vexler,Mohamad A. Hussein,Daniel E. H. Afar +11 more
TL;DR: HuLuc63, a novel humanized anti-CS1 mAb (derived from MuLuc63) was used for functional characterization in non-isotopic LDH-based antibody-dependent cellular cytotoxicity (ADCC) assays, demonstrating that HuLuc63 could be a potential new treatment for multiple myeloma.
Journal ArticleDOI
Elotuzumab (HuLuc63) Activates CD56dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1
Balaji Balasa,Mahrukh Huseni,Jyothi Cherukuri,Roxanne Steinle,Amulya Nanisetti,Daniel E. H. Afar,Eric D. Hsi,Vladimir Vexler +7 more
TL;DR: It is demonstrated that elotuzumab may activate NK cells via CS1 and CD16 signaling, resulting in the release of low levels of IFN-g and subsequently monocyte-dependant chemokine production including IP-10 and MCP-1.
Patent
Polypeptide inhibitors of vla4
Madan M. Paidhungat,Amulya Nanisetti,Thomas Bouquin,Kim Vilbour Andersen,Sarah Patrick,Steven J. Chapin,Dan Youel,Claus M. Krebber,Rong Fan,Daniel Malashock,Amy Brideau-Andersen,Erik E. Karrer,Bruce H. Devens,Steven H. Bass,Myriam Detrinidad +14 more
TL;DR: In this article, a 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4 were provided. And related polynucleotides, compositions, vectors, host cells, and methods.